Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - January 22, 2025 574 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KATHERINE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Cancerul în comunitatea mea: progresul îngrijirilor pentru cancer în România August 4, 2020 Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated... August 20, 2025 FDA Approves Enfortumab Vedotin-ejfv with Pembrolizumab for Locally Advanced or Metastatic... January 8, 2024 Cancer Drug Lynparza Found to Lower Risk of Death and Recurrence... June 4, 2021 Load more HOT NEWS Tailored Psychotherapy Eases Depression in People with Advanced Cancer Treating High-Risk Bladder Cancer and Analyzing PSA Screening for Prostate Cancer:... Aiming to Prevent Cancer Cases, ESMO Campaigns Against the Use of... Two-Step Approach Might Be An Alternative to Standard Three-Step Approach of...
